R&D News | pharmaphorum

News

Pfizer and Roivant launch autoimmune specialist Priovant

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune

News

US panel backs Omicron-targeting vaccines for booster campai...

Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA's Vaccines and Related Biological Produc

News

Basilea preps key US filing for MRSA antibiotic ceftobiprole

Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial.<

News

Study exposes lack of diversity in US cancer trials

Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of

News

GSK hepatitis B hope bepirovirsen heads for phase 3 test

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a

News

DNA helix in a futuristic concept of the evolution of science and medicine.

Another Astellas gene therapy hits a safety hurdle

The safety of Astellas' gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845.

Pfizer and Roivant launch autoimmune specialist Priovant

US panel backs Omicron-targeting vaccines for booster campai...

Basilea preps key US filing for MRSA antibiotic ceftobiprole

Study exposes lack of diversity in US cancer trials

GSK hepatitis B hope bepirovirsen heads for phase 3 test

Another Astellas gene therapy hits a safety hurdle

Moderna's Q1 revenues rocket, thanks to ex-US sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks